Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis

NCT05335928 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05335928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
July 2, 2022
Completion date
October 9, 2029
Enrollment
390 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, myocarditis acute